Figure 2.

In men, a significant interaction between baseline symptom group (high vs lo,w) and hormone condition was identified by ANOVA-R (F_2,20 = 9.7, p < 0.003). Men with high baseline DISF scores (n = 6) had a significant reduction in total DISF scores during hypogonadism compared with both baseline and T-replaced conditions, and a significant increase in DISF scores after T replacement compared with hypogonadism. Men with low baseline DISF scores (n = 6) showed no significant differences in DISF scores across hormone conditions. Similarly, women with high baseline DISF scores (n = 6) showed a significant reduction in DISF scores during hypogonadism (and during estrogen and progesterone conditions) compared with baseline scores, whereas women with low baseline DISF scores (n = 6) showed no significant change across hormone conditions (ANOVA-R group × hormone condition, F_3,30 = 9.8, p = 0.001). In women, total DISF scores were significantly greater in the ‘high’ group at baseline only (t₄₀ = 3.8, p < 0.01; otherwise p = NS). Whereas, in men, total DISF scores were significantly higher in the ‘high’ compared to the ‘low’ baseline symptom group during both baseline and T (t₃₀ = 3.4 and 4.7, respectively, p < 0.01). No significant interactions between subscale scores and group or hormone condition were observed in either men or women.